Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 15/20 | 0.67 |
| ▸ | OPRD1 | P41143 | 14/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20362245 | 1.00 | OPRK1 (0.67) | OPRK1OPRD1TAAR1SLC6A2OPRM1 | |
| Hydrochloric Acid SCHEMBL23002160 | 0.98 | OPRK1 (0.65) | OPRK1OPRD1TAAR1SLC6A2OPRM1 | |
| Hydrochloric Acid SCHEMBL20791714 | 0.98 | OPRK1 (0.65) | OPRK1OPRD1TAAR1SLC6A2OPRM1 | |
| Hydrochloric Acid SCHEMBL20791713 | 0.98 | OPRK1 (0.65) | OPRK1OPRD1TAAR1SLC6A2OPRM1 | |
| SCHEMBL24305562 | 0.82 | OPRD1 (0.55) | OPRK1OPRD1TAAR1SLC6A2OPRM1 | |
| SCHEMBL21447171 | 0.81 | OPRD1 (0.46) | OPRK1OPRD1TAAR1 | |
| SCHEMBL4676268 | 0.80 | OPRK1 (0.50) | OPRK1OPRD1TAAR1SLC6A2 | |
| SCHEMBL42419 | 0.80 | OPRK1 (0.50) | OPRK1OPRD1TAAR1SLC6A2 | |
| Hydrochloric Acid SCHEMBL23405194 | 0.79 | OPRD1 (0.45) | OPRK1OPRD1TAAR1 | |
| Hydrochloric Acid SCHEMBL23405192 | 0.79 | OPRD1 (0.45) | OPRK1OPRD1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12168648-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| CN-112867705-B | Opioid receptor modulators and products and methods related thereto | 埃皮欧黛公司 | 2024-08-20 | — | — | CN | disclosed |
| EP-3774722-B1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240092746-A1 | OPIOID RECEPTOR MODULATORS | EPIODYNE, INC. | 2024-03-21 | — | — | US | disclosed |
| EP-4320105-A1 | OPIOID RECEPTOR MODULATORS | Epiodyne, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117425644-A | Opioid receptor modulators | 埃皮欧黛公司 | 2024-01-19 | — | — | CN | disclosed |
| US-11634396-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11634396-B2 | Opioid receptor modulators | EPIODYNE, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220356157-A1 | OPIOID RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-11-10 | — | — | US | disclosed |
| WO-2022216750-A1 | OPIOID RECEPTOR MODULATORS | EPIODYNE, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
| US-20210052548-A1 | MU OPIOID RECEPTOR MODULATORS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2021-02-25 | — | — | US | disclosed |
| US-10702498-B2 | MU opioid receptor modulators | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200109126-A1 | MU OPIOID RECEPTOR MODULATORS | UNIV CALIFORNIA (US) | 2020-04-09 | — | — | US | disclosed |
| US-20200109126-A1 | MU OPIOID RECEPTOR MODULATORS | UNIV CALIFORNIA (US) | 2020-04-09 | — | — | US | disclosed |
| EP-3565543-A1 | MU OPIOID RECEPTOR MODULATORS | The Regents of The University of California (US) | 2019-11-13 | — | — | EP | disclosed |
| WO-2019195634-A1 | OPIOID RECEPTOR MODULATORS AND PRODUCTS AND METHODS RELATED THERETO | EPIODYNE, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190076398-A1 | MU OPIOID RECEPTOR MODULATORS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2019-03-14 | — | — | US | disclosed |
| WO-2018129393-A1 | MU OPIOID RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018129393-A1 | MU OPIOID RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2017007695-A1 | MU OPIOID RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092746-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | OPRK1 2/4885OPRD1 4/4885TAAR1 173/4885 |
| US-12168648-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | OPRK1 2/4885OPRD1 4/4885TAAR1 173/4885 |
| US-10702498-B2 | MU opioid receptor modulators | OPRM1, OPRK1, OPRD1 | OPRK1 2/4885OPRD1 3/4885TAAR1 115/4885 |
| US-11634396-B2 | Opioid receptor modulators | OPRM1, OPRK1, OPRL1 | OPRK1 2/4885OPRD1 4/4885TAAR1 173/4885 |
| US-20220356157-A1 | OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRL1 | OPRK1 2/4885OPRD1 4/4885TAAR1 173/4885 |
| US-20190076398-A1 | MU OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRD1 | OPRK1 2/4885OPRD1 3/4885TAAR1 115/4885 |
| US-20210052548-A1 | MU OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRD1 | OPRK1 2/4885OPRD1 3/4885TAAR1 115/4885 |
| US-20200109126-A1 | MU OPIOID RECEPTOR MODULATORS | OPRM1, OPRK1, OPRD1 | OPRK1 2/4885OPRD1 3/4885TAAR1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.